Dakarai E. Esgdaille
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Dakarai E. Esgdaille has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Paul L. Boutz
Department of Biochemistry and Biophysics, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA
2 shared publications - Anna M. Cox
Stem Cell Program and Division of Hematology/Oncology, Boston Children’s Hospital, Howard Hughes Medical Institute, Boston, MA 02115, USA
1 shared publication - Benjamin J. E. Martin
Department of Biological Chemistry and Molecular Pharmacology, Blavatnik Institute, Harvard Medical School, Boston, MA 02115, USA
1 shared publication - Brian J. Abraham
Department of Computational Biology, St. Jude Children’s Research Hospital, Memphis, USA
1 shared publication - Calvin Gerald Ludwig
Stem Cell Program and Division of Hematology/Oncology, Boston Children’s Hospital, Howard Hughes Medical Institute, Boston, USA
1 shared publication - Constance Wu
Stem Cell Program and Division of Hematology/Oncology, Boston Children’s Hospital, Howard Hughes Medical Institute, Boston, MA 02115, USA
1 shared publication
Latest Publications
- Open Access
- 17 October 2026
- Published by Springer Nature in Cell Death Discovery
Long non-coding RNA NEAT1 drives nuclear condensates regulating gene expression and ferroptosis vulnerability in pancreatic cancer cells
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with poor patient outcomes due to development of tumor cell drug resistance impacting treatment efficacy. Shifts in tumor cell transcriptional subtypes from well-differentiated classical to poorly differentiated basal-like cells can drive PDAC chemotherapeutic resistance. Such transcriptomic changes have been linked to cellular metabolic states, but how coordination of transcriptional and metabolic programs is mediated at the molecular level remains unclear. The stress-responsive long noncoding RNA NEAT1 , an essential constituent of nuclear condensates called paraspeckles, has been associated with classical PDAC and was previously linked to regulation of cellular metabolism. In this study, we utilized a high-throughput drug screening approach in NEAT1 -deficient cancer cells to uncover functional metabolic targets in these cells, identifying ferroptosis via GPX4 inhibition as a major vulnerability of cells lacking paraspeckles. We find that the paraspeckle-forming isoform of NEAT1 is central to ferroptosis suppression, and we extend these results into PDAC cell line models with genetic suppression or activation of NEAT1 . We find that NEAT1 -nucleated paraspeckles underlie the expression program tied to the classical PDAC subtype and promote ferroptosis resistance. We pinpoint the paraspeckle-suppressive RNA-binding protein QKI, associated with basal-like PDAC, as a positive regulator of ferroptosis susceptibility, possibly through its suppression of paraspeckles. These results link NEAT1 and regulation of paraspeckle condensates to subtype-specific ferroptosis susceptibility in PDAC and offer novel avenues for targeting metabolic vulnerabilities of pancreatic cancer cells on the basis of transcriptional subtype.
- 17 October 2026
- Published by Springer Nature in Cell Death Discovery
Open AccessLong non-coding RNA NEAT1 drives nuclear condensates regulating gene expression and ferroptosis vulnerability in pancreatic cancer cells
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with poor patient outcomes due to development of tumor cell drug resistance impacting treatment efficacy. Shifts in tumor cell transcriptional subtypes from well-differentiated classical to poorly differentiated basal-like cells can drive PDAC chemotherapeutic resistance. Such transcriptomic changes have been linked to cellular metabolic states, but how coordination of transcriptional and metabolic programs is mediated at the molecular level remains unclear. The stress-responsive long noncoding RNA NEAT1 , an essential constituent of nuclear condensates called paraspeckles, has been associated with classical PDAC and was previously linked to regulation of cellular metabolism. In this study, we utilized a high-throughput drug screening approach in NEAT1 -deficient cancer cells to uncover functional metabolic targets in these cells, identifying ferroptosis via GPX4 inhibition as a major vulnerability of cells lacking paraspeckles. We find that the paraspeckle-forming isoform of NEAT1 is central to ferroptosis suppression, and we extend these results into PDAC cell line models with genetic suppression or activation of NEAT1 . We find that NEAT1 -nucleated paraspeckles underlie the expression program tied to the classical PDAC subtype and promote ferroptosis resistance. We pinpoint the paraspeckle-suppressive RNA-binding protein QKI, associated with basal-like PDAC, as a positive regulator of ferroptosis susceptibility, possibly through its suppression of paraspeckles. These results link NEAT1 and regulation of paraspeckle condensates to subtype-specific ferroptosis susceptibility in PDAC and offer novel avenues for targeting metabolic vulnerabilities of pancreatic cancer cells on the basis of transcriptional subtype.
- 21 April 2023
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 380 (6642) , eabn7625
Oncogenic CDK13 mutations impede nuclear RNA surveillance
RNA surveillance pathways detect and degrade defective transcripts to ensure RNA fidelity. We found that disrupted nuclear RNA surveillance is oncogenic. Cyclin-dependent kinase 13 ( CDK13 ) is mutated in melanoma, and patient-mutated CDK13 accelerates zebrafish melanoma. CDK13 mutation causes aberrant RNA stabilization. CDK13 is required for ZC3H14 phosphorylation, which is necessary and sufficient to promote nuclear RNA degradation. Mutant CDK13 fails to activate nuclear RNA surveillance, causing aberrant protein-coding transcripts to be stabilized and translated. Forced aberrant RNA expression accelerates melanoma in zebrafish. We found recurrent mutations in genes encoding nuclear RNA surveillance components in many malignancies, establishing nuclear RNA surveillance as a tumor-suppressive pathway. Activating nuclear RNA surveillance is crucial to avoid accumulation of aberrant RNAs and their ensuing consequences in development and disease.
- 21 April 2023
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 380 (6642) , eabn7625
Oncogenic CDK13 mutations impede nuclear RNA surveillance
RNA surveillance pathways detect and degrade defective transcripts to ensure RNA fidelity. We found that disrupted nuclear RNA surveillance is oncogenic. Cyclin-dependent kinase 13 ( CDK13 ) is mutated in melanoma, and patient-mutated CDK13 accelerates zebrafish melanoma. CDK13 mutation causes aberrant RNA stabilization. CDK13 is required for ZC3H14 phosphorylation, which is necessary and sufficient to promote nuclear RNA degradation. Mutant CDK13 fails to activate nuclear RNA surveillance, causing aberrant protein-coding transcripts to be stabilized and translated. Forced aberrant RNA expression accelerates melanoma in zebrafish. We found recurrent mutations in genes encoding nuclear RNA surveillance components in many malignancies, establishing nuclear RNA surveillance as a tumor-suppressive pathway. Activating nuclear RNA surveillance is crucial to avoid accumulation of aberrant RNAs and their ensuing consequences in development and disease.